Clinical trials - page 7

Use of Virtual Reality Mask or Music Therapy for Analgesia and Anxiolytic Purpose When Totally Implanted Venous Access Device (IVAD) for Chemotherapy Under Local Anesthesia

A multicentric randomized phase II/III evaluating TSR-042 (anti-PD-1 mAb) in combination with Niraparib (parpi) versus Niraparib alone compared to chemotherapy in the treatment of metastatic or recurrent endometrial or ovarian carcinosarcoma after at least one line of chemotherapy

A phase 3, open-label, randomized, controlled study aimed at evaluating the efficacy and safety of petosemtamab compared to the investigator's choice of monotherapy in previously treated patients with metastatic/recurring, incurable head and neck squamous cell carcinoma

A Randomised, Open-Label, Phase III Study of AZD5305 Plus Camizestrant versus Physician's Choice CDK4/6 Inhibitor Plus Endocrine Therapy for the First-Line Treatment of BRCA1, BRCA2, or PALB2-mutated Patients with Hormone Receptor-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer ().

Clinical trial of precision medicine in patients with advanced biliary tract cancers (cholangiocarcinoma or gallbladder cancer).

LUNAR-2: a pivotal, randomized, open-label trial of Tumor Treating Fields (TTFields, 150 kHz) combined with pembrolizumab and platinum-based chemotherapy in the treatment of metastatic non·small cell lung cancer.

The BGB-58067-101 study is a Phase 1a/1b clinical trial evaluating BGB-58067, a selective MTA-cooperative PRMT5 inhibitor, in patients with advanced solid tumors harboring homozygous MTAP deletion.

Phase 3, randomized, double-blind, multicenter study evaluating the combination of BMS-986489 (a fixed-dose combination of Nivolumab and BMS-986012) with carboplatin and etoposide versus the combination of Atezolizumab with carboplatin and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer (ES-SCLC).

A Phase III, Open-label, Randomised Study of Osimertinib;With or Without Datopotamab Deruxtecan (Dato-DXd), as;First-line Treatment in Participants With Epidermal Growth;Factor Receptor (EGFR) Mutation-positive, Locally Advanced;or Metastatic Non-small Cell Lung Cancer;(TROPION-Lung14)

the Impact of Occupational Therapy : a Multicenter Randomized Controlled Trial (OCEAN-OT).

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (EVOKE-SCLC-04).

Phase·Ib/II, multicenter, open-label study evaluating BDC-1001, a HER2-targeted TLR7/8 agonist antibody-drug conjugate, as monotherapy and in combination with nivolumab in advanced HER2-expressing solid tumors.

Impact of 18F-FES PET on the Therapeutic Treatment of Patients With Metastatic Breast Cancer (ESTROTIMP)

A randomised Phase III trial with a factorial design evaluating the efficacy and safety of darolutamide and stereotactic dose escalated radiotherapy in patients with localised prostate cancer and high-risk features of relapse, from the Prostate Cancer Consortium in Europe (PEACE).

A Phase 2, randomized, open-label, active-controlled study of JNJ-90301900 in;combination with chemoradiation followed by durvalumab in locally advanced and;unresectable Stage III non-small cell lung cancer